SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:umu-57187"
 

Sökning: id:"swepub:oai:DiVA.org:umu-57187" > Triacylglycerol-ric...

Triacylglycerol-rich lipoproteins protect lipoprotein lipase from inactivation by ANGPTL3 and ANGPTL4

Nilsson, Stefan (författare)
Umeå universitet,Fysiologisk kemi
Anderson, Fredrick (författare)
Umeå universitet,Fysiologisk kemi
Ericsson, Madelene (författare)
Umeå universitet,Fysiologisk kemi
visa fler...
Larsson, Mikael (författare)
Umeå universitet,Fysiologisk kemi
Makoveychuk, Elena (författare)
Umeå universitet,Fysiologisk kemi
Lookene, Aivar (författare)
Umeå universitet,Fysiologisk kemi
Heeren, Joerg (författare)
Olivecrona, Gunilla (författare)
Umeå universitet,Fysiologisk kemi
visa färre...
 (creator_code:org_t)
Amsterdam : Elsevier, 2012
2012
Engelska.
Ingår i: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. - Amsterdam : Elsevier. - 1388-1981 .- 1879-2618. ; 1821:10, s. 1370-1378
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Lipoprotein lipase (LPL) is important for clearance of triacylglycerols (TG) from plasma both as an enzyme and as a bridging factor between lipoproteins and receptors for endocytosis. The amount of LPL at the luminal side of the capillary endothelium determines to what extent lipids are taken up. Mechanisms to control both the activity of LPL and its transport to the endothelial sites are regulated, but poorly understood. Angiopoietin-like proteins (ANGPTLs) 3 and 4 are potential control proteins for LPL, but plasma concentrations of ANGPTLs do not correlate with plasma TG levels. We investigated the effects of recombinant human N-terminal (NT) ANGPTLs3 and 4 on LPL-mediated bridging of TG-rich lipoproteins to primary mouse hepatocytes and found that the NT-ANGPTLs, in concentrations sufficient to cause inactivation of LPL in vitro, were unable to prevent LPL-mediated lipoprotein uptake. We therefore investigated the effects of lipoproteins (chylomicrons, VLDL and LDL) on the inactivation of LPL in vitro by NT-ANGPTLs3 and 4 and found that LPL activity was protected by TG-rich lipoproteins. In vivo, postprandial TG protected LPL from inactivation by recombinant NT-ANGPTL4 injected to mice. We conclude that lipoprotein-bound LPL is stabilized against inactivation by ANGPTLs. The levels of ANGPTLs found in blood may not be sufficient to overcome this stabilization. Therefore it is likely that the prime site of action of ANGPTLs on LPL is in subendothelial compartments where TG-rich lipoprotein concentration is lower than in blood. This could explain why the plasma levels of TG and ANGPTLs do not correlate.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Annan medicin och hälsovetenskap (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Other Medical and Health Sciences (hsv//eng)

Nyckelord

ANGPTL3
ANGPTL4
Lipoprotein lipase
Triacylglycerol metabolism
VLDL
Chylomicron
medicin
Medicine

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy